Tab%2525252525252525252525252525252520rizatriptan

# Rizatriptan ## Overview Rizatriptan is a selective serotonin (5-HT1B/1D) receptor agonist used for the acute treatment of migraine. It induces vasoconstriction of intracranial blood vessels and inhibits the release of pro-inflammatory neuropeptides. It is available as standard tablets and orally disintegrating tablets (ODTs). ## Primary Indications Acute treatment of migraine attacks with or without aura in adults and pediatric patients (6–17 years). Not indicated for migraine prophylaxis or management of hemiplegic or basilar migraine. ## Adult Dosing * **Standard Dose:** 5 mg or 10 mg at onset of migraine. * **Dosing Interval:** If symptoms persist or recur, dose may be repeated after a minimum of 2 hours. * **Maximum Dose:** 30 mg in a 24-hour period. ## Pediatric Dosing (6–17 years) * **Weight < 40 kg:** 5 mg dose. * **Weight ≥ 40 kg:** 10 mg dose. * **Maximum Dose:** Single dose only per 24-hour period. Safety of repeated dosing in pediatrics has not been formally established. ## Dose Adjustments * **Renal/Hepatic Impairment:** No specific adjustment required; however, clinical experience is limited in severe impairment. * **Concomitant Propranolol:** Use 5 mg dose. Propranolol increases rizatriptan plasma concentrations. Maximum daily dose is 15 mg. ## Contraindications * History of ischemic heart disease (e.g., angina, MI, silent ischemia). * Coronary artery vasospasm (Prinzmetal’s angina). * Wolff-Parkinson-White syndrome or arrhythmias associated with accessory conduction pathways. * History of stroke or transient ischemic attack (TIA). * Peripheral vascular disease. * Uncontrolled hypertension. * Use within 24 hours of another 5-HT1 agonist or ergotamine-type medication. * Use within 14 days of monoamine oxidase inhibitor (MAOI) therapy. ## Adverse Effects * **Common:** Dizziness, somnolence, paresthesia, fatigue, xerostomia, and chest tightness/pressure. * **Serious:** Coronary artery vasospasm, myocardial infarction, arrhythmias, stroke, and serotonin syndrome (especially when combined with SSRIs/SNRIs). ## Key Drug Interactions * **MAOIs:** Significant risk of increased rizatriptan toxicity; strictly contraindicated. * **Propranolol:** Increases rizatriptan bioavailability; dose must be halved. * **Serotonergic Agents (SSRIs/SNRIs):** May increase risk of serotonin syndrome; monitor for symptoms (agitation, tachycardia, hyperreflexia). * **Ergot derivatives:** Do not administer within 24 hours due to additive vasospastic effects. ## Monitoring * Monitor blood pressure during the first administration in patients with cardiovascular risk factors. * Assess for chest, jaw, or neck pain indicative of cardiac ischemia post-dose. * Monitor for signs of serotonin syndrome if combined with other serotonergic medications. ## Clinical Pearls * **ODT formulation:** The blister pack must be kept dry until use; the tablet should be placed on the tongue and allowed to dissolve. Water is not needed for the ODT, but the patient may drink liquids if desired. * **Efficacy:** Effectiveness is independent of the migraine headache duration at the time of intake, though earlier administration often yields better results. * **Medication Overuse Headache (MOH):** Excessive use (typically ≥10 days per month) can lead to medication overuse headache; advise patients to limit frequency. *** **Educational Disclaimer:** This information is intended for educational purposes for healthcare professionals. Clinical practice guidelines and drug labeling may change. Always consult the most current manufacturer prescribing information, local clinical protocols, and pharmacy databases (e.g., Lexicomp, Micromedex) before prescribing or administering medication.